AP NEWS

Medidata Rave Engage Wins Scrip Award for Best Sponsor-Focused Technological Development in Clinical Trials

November 30, 2018

NEW YORK--(BUSINESS WIRE)--Nov 30, 2018--Medidata (NASDAQ:MDSO) is pleased to announce that Rave Engage was recognized at the 2018 Scrip Awards as the “Best Technological Development in Clinical Trials - Tech Sponsor Focused.” This marks the third consecutive Scrip Award win for the company.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181130005221/en/

(Graphic: Business Wire)

Medidata Rave Engage is an intuitive web-based application that serves as the patient-facing interface for virtual trials and hybrid studies that seek to reduce physical site visits. Patients remain engaged throughout the study with what Medidata calls the “Trial Dial,” which enables sponsors to choose the right balance of site-based and virtual visits. Through Rave Engage, sponsors and investigators improve operational efficiency, scalability, and patient recruitment and retention—all of which result in better data and lower trial costs.

Presented to Medidata at the 14th Annual Scrip Awards on November 28, 2018 in London, the award celebrates excellence and innovation in the biopharmaceutical industry and a continued commitment to improving healthcare on a global scale. A panel of judges—comprised of independent, senior industry experts from around the world—evaluated a record number of submissions across a wide range of categories, announcing a shortlist of finalists earlier this year.

“Medidata Rave Engage improves the entire patient and sponsor experience with clinical trial virtualization,” said Anthony Costello, vice president, mHealth, Medidata. “Modern clinical trials, especially large-scale trials, need to be more efficiently run and convenient for patients. We believe that virtual and hybrid trials, made possible by Rave Engage and the Medidata platform, are the future of clinical research.”

Rave Engage currently powers a number of virtual studies for global pharmaceutical and biopharmaceutical companies, including the well-publicized aspirin study, ADAPTABLE—the largest virtual trial ever conducted, with an enrollment target of 15,000 patients. With the Rave Engage platform, ADAPTABLE patients are virtually enrolled, consented, and randomized to provide their own reported outcome throughout the study with no physical site visits.

About Medidata

Medidata is leading the digital transformation of life sciences, with the world’s most used platform for clinical development, commercial, and real-world data. Powered by artificial intelligence and delivered by the #1 ranked industry experts, the Intelligent Platform for Life Sciences helps pharmaceutical, biotech, medical device companies, and academic researchers accelerate value, minimize risk and optimize outcomes. Medidata serves more than 1,000 customers and partners worldwide and empowers more than 100,000 certified users every day to create hope for millions of patients. Discover the future of life sciences: www.mdsol.com

View source version on businesswire.com:https://www.businesswire.com/news/home/20181130005221/en/

CONTACT: Medidata Solutions

Investors:

Betsy Frank, +1 917-522-4620

bfrank@mdsol.com

Media:

Erik Snider, +1 646-362-2997

esnider@mdsol.com

KEYWORD: UNITED STATES NORTH AMERICA NEW YORK

INDUSTRY KEYWORD: TECHNOLOGY DATA MANAGEMENT INTERNET OTHER TECHNOLOGY HEALTH BIOTECHNOLOGY CLINICAL TRIALS PHARMACEUTICAL MOBILE/WIRELESS RESEARCH OTHER SCIENCE SCIENCE GENERAL HEALTH

SOURCE: Medidata

Copyright Business Wire 2018.

PUB: 11/30/2018 08:45 AM/DISC: 11/30/2018 08:45 AM

http://www.businesswire.com/news/home/20181130005221/en

AP RADIO
Update hourly